目的 :研究美罗培南在肺炎囊性纤维化病人体内的药物动力学。 方法 :6例成年肺炎囊性纤维化住院病人 ,静脉滴注给予美罗培南 2 g q8h,用 HPLC法测定血药浓度。采用 3 P87程序统计矩方法求算药代动力学参数。结果 :美罗培南的体内过程符合二室开放模型 ,其药物动力学参数分别为 :tm ax=(0 .5 742± 0 .0 2 0 7) h,cm ax=(14 1.7± 40 .48) μg/ml,AUC=(14 8.7± 2 3 .42 ) μg·h· ml-1 ,t1 /2β=(1.168± 0 .2 78) h,与常规剂量一致。 结论 :肺炎囊性纤维化病人应用高剂量美罗培南时 ,具有良好的安全性和很好的临床疗效 Objective: To study the pharmacokinetics of Meropenem in patients with pneumocystic fibrosis. Methods: Six adult pneumonia patients with cystic fibrosis were infused intravenously with Meropenem 2 g q8h, and the blood concentration was determined by HPLC. Pharmacokinetic parameters were calculated using the 3 P87 program statistical moment method. Results: The in vivo process of meropenem conformed to the two-compartment open model and its pharmacokinetic parameters were: tm ax = (0.5742 ± 0.0207) h, cm ax = (14 1.7 ± 40.48) μg / ml, AUC = (14 8.7 ± 23.42) μg · h · ml-1, t1 / 2β = (1.168 ± 0.278) h, consistent with the conventional dose. Conclusions: The use of high-dose meropenem in patients with pneumocystic fibrosis has good safety and good clinical efficacy